Preclinical efficacy of sodium narcistatin to reduce inflammation and joint destruction in rats with adjuvant-induced arthritis

Cheri Lubahn, Jill A. Schaller, Eric Shewmacker, Carlo Wood, Denise L. Bellinger, Donna Byron, Noeleen Melody, George Pettit, Dianne Lorton

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Current therapies for the treatment of rheumatoid arthritis (RA) do not work for all patients, can lose efficacy over time, and can have significant side eVects. The discovery of new, eVective therapies for RA remains an unmet medical need. The Amaryllidaceae isocarbostyril narciclasine was previously shown to prophylactically reduce paw swelling in rats with adjuvant-induced arthritis (AA). In this study, the efficacy of sodium narcistatin (SNS), a water-soluble cyclic phosphate pro-drug of narciclasine, was assessed in AA rats for anti-inflammatory and bone-sparing properties after disease onset. AA rats were given daily intraperitoneal injections of SNS (1.75, 3.5, or 5 mg/kg/day, in 500 ?l sterile endotoxin-free saline) or saline from disease onset through severe disease stages. Footpad widths and radiographic scoring were used as indicators of inflammation and joint destruction, respectively. Ex vivo cytokine production by peripheral blood mononuclear cells (PMBC), splenocytes, and draining lymph node (DLN) cells were determined using ELISAs. SNS treatment dose-dependently reduced joint inflammation (̃70%) and bone loss (̃50%) compared with AA controls. SNS treatment also reduced spleen weight (without aVecting body weight), pro-inflammatory cytokine production by PMBC, splenocytes, and DLN cells, and site-dependently altered Thelper (Th)1-/Th2-type and anti-inflammatory cytokine profiles. SNS dramatically reduces inflammation and has bone-sparing properties, possibly by reducing immune cell pro-inflammatory cytokine production. Our Wndings support the development of SNS as a therapeutic for RA.

Original languageEnglish (US)
Pages (from-to)3751-3760
Number of pages10
JournalRheumatology International
Volume32
Issue number12
DOIs
StatePublished - Dec 2012

Fingerprint

Experimental Arthritis
Joints
Sodium
Inflammation
Cytokines
Osteitis
Rheumatoid Arthritis
Anti-Inflammatory Agents
Therapeutics
Lymph Nodes
Prodrugs
Intraperitoneal Injections
Endotoxins
narcistatin
Blood Cells
Spleen
Enzyme-Linked Immunosorbent Assay
Phosphates
Body Weight
Weights and Measures

Keywords

  • Adjuvant-induced arthritis
  • Bone destruction
  • Cytokines
  • InXammation
  • Rheumatoid arthritis
  • Sodium narcistatin

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Lubahn, C., Schaller, J. A., Shewmacker, E., Wood, C., Bellinger, D. L., Byron, D., ... Lorton, D. (2012). Preclinical efficacy of sodium narcistatin to reduce inflammation and joint destruction in rats with adjuvant-induced arthritis. Rheumatology International, 32(12), 3751-3760. https://doi.org/10.1007/s00296-011-2217-z

Preclinical efficacy of sodium narcistatin to reduce inflammation and joint destruction in rats with adjuvant-induced arthritis. / Lubahn, Cheri; Schaller, Jill A.; Shewmacker, Eric; Wood, Carlo; Bellinger, Denise L.; Byron, Donna; Melody, Noeleen; Pettit, George; Lorton, Dianne.

In: Rheumatology International, Vol. 32, No. 12, 12.2012, p. 3751-3760.

Research output: Contribution to journalArticle

Lubahn, Cheri ; Schaller, Jill A. ; Shewmacker, Eric ; Wood, Carlo ; Bellinger, Denise L. ; Byron, Donna ; Melody, Noeleen ; Pettit, George ; Lorton, Dianne. / Preclinical efficacy of sodium narcistatin to reduce inflammation and joint destruction in rats with adjuvant-induced arthritis. In: Rheumatology International. 2012 ; Vol. 32, No. 12. pp. 3751-3760.
@article{316ad008f17143739be77f968ecef438,
title = "Preclinical efficacy of sodium narcistatin to reduce inflammation and joint destruction in rats with adjuvant-induced arthritis",
abstract = "Current therapies for the treatment of rheumatoid arthritis (RA) do not work for all patients, can lose efficacy over time, and can have significant side eVects. The discovery of new, eVective therapies for RA remains an unmet medical need. The Amaryllidaceae isocarbostyril narciclasine was previously shown to prophylactically reduce paw swelling in rats with adjuvant-induced arthritis (AA). In this study, the efficacy of sodium narcistatin (SNS), a water-soluble cyclic phosphate pro-drug of narciclasine, was assessed in AA rats for anti-inflammatory and bone-sparing properties after disease onset. AA rats were given daily intraperitoneal injections of SNS (1.75, 3.5, or 5 mg/kg/day, in 500 ?l sterile endotoxin-free saline) or saline from disease onset through severe disease stages. Footpad widths and radiographic scoring were used as indicators of inflammation and joint destruction, respectively. Ex vivo cytokine production by peripheral blood mononuclear cells (PMBC), splenocytes, and draining lymph node (DLN) cells were determined using ELISAs. SNS treatment dose-dependently reduced joint inflammation (̃70{\%}) and bone loss (̃50{\%}) compared with AA controls. SNS treatment also reduced spleen weight (without aVecting body weight), pro-inflammatory cytokine production by PMBC, splenocytes, and DLN cells, and site-dependently altered Thelper (Th)1-/Th2-type and anti-inflammatory cytokine profiles. SNS dramatically reduces inflammation and has bone-sparing properties, possibly by reducing immune cell pro-inflammatory cytokine production. Our Wndings support the development of SNS as a therapeutic for RA.",
keywords = "Adjuvant-induced arthritis, Bone destruction, Cytokines, InXammation, Rheumatoid arthritis, Sodium narcistatin",
author = "Cheri Lubahn and Schaller, {Jill A.} and Eric Shewmacker and Carlo Wood and Bellinger, {Denise L.} and Donna Byron and Noeleen Melody and George Pettit and Dianne Lorton",
year = "2012",
month = "12",
doi = "10.1007/s00296-011-2217-z",
language = "English (US)",
volume = "32",
pages = "3751--3760",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "12",

}

TY - JOUR

T1 - Preclinical efficacy of sodium narcistatin to reduce inflammation and joint destruction in rats with adjuvant-induced arthritis

AU - Lubahn, Cheri

AU - Schaller, Jill A.

AU - Shewmacker, Eric

AU - Wood, Carlo

AU - Bellinger, Denise L.

AU - Byron, Donna

AU - Melody, Noeleen

AU - Pettit, George

AU - Lorton, Dianne

PY - 2012/12

Y1 - 2012/12

N2 - Current therapies for the treatment of rheumatoid arthritis (RA) do not work for all patients, can lose efficacy over time, and can have significant side eVects. The discovery of new, eVective therapies for RA remains an unmet medical need. The Amaryllidaceae isocarbostyril narciclasine was previously shown to prophylactically reduce paw swelling in rats with adjuvant-induced arthritis (AA). In this study, the efficacy of sodium narcistatin (SNS), a water-soluble cyclic phosphate pro-drug of narciclasine, was assessed in AA rats for anti-inflammatory and bone-sparing properties after disease onset. AA rats were given daily intraperitoneal injections of SNS (1.75, 3.5, or 5 mg/kg/day, in 500 ?l sterile endotoxin-free saline) or saline from disease onset through severe disease stages. Footpad widths and radiographic scoring were used as indicators of inflammation and joint destruction, respectively. Ex vivo cytokine production by peripheral blood mononuclear cells (PMBC), splenocytes, and draining lymph node (DLN) cells were determined using ELISAs. SNS treatment dose-dependently reduced joint inflammation (̃70%) and bone loss (̃50%) compared with AA controls. SNS treatment also reduced spleen weight (without aVecting body weight), pro-inflammatory cytokine production by PMBC, splenocytes, and DLN cells, and site-dependently altered Thelper (Th)1-/Th2-type and anti-inflammatory cytokine profiles. SNS dramatically reduces inflammation and has bone-sparing properties, possibly by reducing immune cell pro-inflammatory cytokine production. Our Wndings support the development of SNS as a therapeutic for RA.

AB - Current therapies for the treatment of rheumatoid arthritis (RA) do not work for all patients, can lose efficacy over time, and can have significant side eVects. The discovery of new, eVective therapies for RA remains an unmet medical need. The Amaryllidaceae isocarbostyril narciclasine was previously shown to prophylactically reduce paw swelling in rats with adjuvant-induced arthritis (AA). In this study, the efficacy of sodium narcistatin (SNS), a water-soluble cyclic phosphate pro-drug of narciclasine, was assessed in AA rats for anti-inflammatory and bone-sparing properties after disease onset. AA rats were given daily intraperitoneal injections of SNS (1.75, 3.5, or 5 mg/kg/day, in 500 ?l sterile endotoxin-free saline) or saline from disease onset through severe disease stages. Footpad widths and radiographic scoring were used as indicators of inflammation and joint destruction, respectively. Ex vivo cytokine production by peripheral blood mononuclear cells (PMBC), splenocytes, and draining lymph node (DLN) cells were determined using ELISAs. SNS treatment dose-dependently reduced joint inflammation (̃70%) and bone loss (̃50%) compared with AA controls. SNS treatment also reduced spleen weight (without aVecting body weight), pro-inflammatory cytokine production by PMBC, splenocytes, and DLN cells, and site-dependently altered Thelper (Th)1-/Th2-type and anti-inflammatory cytokine profiles. SNS dramatically reduces inflammation and has bone-sparing properties, possibly by reducing immune cell pro-inflammatory cytokine production. Our Wndings support the development of SNS as a therapeutic for RA.

KW - Adjuvant-induced arthritis

KW - Bone destruction

KW - Cytokines

KW - InXammation

KW - Rheumatoid arthritis

KW - Sodium narcistatin

UR - http://www.scopus.com/inward/record.url?scp=84872277929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872277929&partnerID=8YFLogxK

U2 - 10.1007/s00296-011-2217-z

DO - 10.1007/s00296-011-2217-z

M3 - Article

VL - 32

SP - 3751

EP - 3760

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 12

ER -